Santen Fortifies Glaucoma Strategy With Sepetaprost Japan Filing
Executive Summary
The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.